About MegaPro Biomedical
MegaPro Biomedical is a company based in Hsinchu (Taiwan) founded in 2014. The company has 27 employees as of December 31, 2024. MegaPro Biomedical operates in a competitive market with competitors including Freeline, Imbed Biosciences, Disc Medicine, Alentis Therapeutics and Keros Therapeutics, among others.
- Headquarter Hsinchu, Taiwan
- Employees 27 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Megapro Biomedical Co., Ltd.
-
Annual Revenue
$14 K-22.22as on Dec 31, 2024
-
Net Profit
-$164.04 M-28.61as on Dec 31, 2024
-
EBITDA
-$162.99 M-31.58as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
27
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MegaPro Biomedical
MegaPro Biomedical is a publicly listed company on the TPEX with ticker symbol 6827 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of MegaPro Biomedical
Detailed funding history for MegaPro Biomedical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MegaPro Biomedical
Investment portfolio details for MegaPro Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MegaPro Biomedical
Detailed financials for MegaPro Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Megapro Biomedical Comparisons
Peer comparison for MegaPro Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MegaPro Biomedical
MegaPro Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Imbed Biosciences, Disc Medicine, Alentis Therapeutics and Keros Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of hematologic diseases
|
|
| Locked | Locked | Locked |
Therapies for fibrosis, cirrhosis, and liver cancer are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
Detailed competitors of MegaPro Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Megapro Biomedical
Complete news archive for MegaPro Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MegaPro Biomedical
MegaPro Biomedical was founded in 2014.
MegaPro Biomedical is headquartered in Hsinchu, Taiwan.
Jassy Wang is the current CEO of MegaPro Biomedical.
As of Dec 31, 2024, the latest employee count at MegaPro Biomedical is 27.
MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.
MegaPro Biomedical's top competitors include Imbed Biosciences, Keros Therapeutics and Disc Medicine.
Yes, MegaPro Biomedical is publicly traded on TPEX under the ticker symbol 6827.
The ticker symbol of MegaPro Biomedical is 6827 on TPEX.